财务附注中报表的单位为：元 1、合并资产负债表 编制单位：奥园美谷科技股份有限公司 2025 年 06 月 30 日 奥园美谷科技股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 法定代表人：范时杰 主管会计工作负责人：江永标 会计机构负责人：江永标 2、母公司资产负债表 项目 期末余额 期初余额 流动资产： 货币资金 2,039,022.35 1,172,282.51 交易性金融资产 衍生金融资产 应收票据 应收账款 5,104,110.18 5,117,480.48 应收款项融资 预付款项 52,274.80 1,000.00 其他应收款 930,355,901.38 935,831,844.84 其中：应收利息 应收股利 存货 其中：数据资源 合同资产 持有待售资产 一年内到期的非流动资产 其他流动资产 6,933,845.85 6,937,618.70 流动资产合计 944,485,154.56 949,060,226.53 非流动资产： 债权投资 其他债权投资 长期应收款 长期股权投资 910,441,082.06 ...

证券代码：000615 证券简称：*ST美谷 公告编号：2025-076 奥园美谷科技股份有限公司 关于预重整事项进展暨收到预重整延期决定书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 2、法院受理重整申请后，公司股票交易存在被实施退市风险警示的风险。 根据《深圳证券交易所股票上市规则（2025 年修订）》（以下简称《股票 上市规则》）第 9.4.1 条第（九）项规定，若法院裁定受理申请人对公司的重 整申请，公司股票将因此被实施退市风险警示。敬请广大投资者注意投资风险。 3、若重整失败宣告破产，公司股票交易可能存在被终止上市的风险。 如果法院受理申请人对公司的重整申请且重整顺利实施完毕，将有利于改 善公司的资产负债结构，推动公司健康发展；但即使法院正式受理重整申请， 后续仍然存在因重整失败而被宣告破产并被实施破产清算的风险。若重整失败， 公司将存在被宣告破产的风险。如果公司被宣告破产，根据《股票上市规则》 的相关规定，公司股票将面临被终止上市的风险。敬请广大投资者注意投资风 险。 敬请广大投资者关注本公告风险提示内容，谨慎决策、注意投资风险。 1 重 ...

特此公告。 证券代码：000615 证券简称：*ST美谷 公告编号：2025-074 奥园美谷科技股份有限公司 第十一届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）第十一届监事会第十四次 会议通知于2025年8月16日上午以电子通讯方式通知公司全体监事，会议于2025 年 8 月 26 日下午以现场会议的方式召开。本次会议由监事会主席赵满女士主持， 会议应到监事 3 人，实到监事 3 人。会议的召集、召开程序符合《中华人民共和 国公司法》和《公司章程》的有关规定。经与会监事认真审议，通过了如下决议： 审议通过了《2025 年半年度报告全文及摘要》 经审核，监事会认为：董事会编制和审核公司《2025 年半年度报告全文》及 摘要的程序符合法律、法规和中国证监会、深圳证券交易所的规定，报告内容真 实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 奥园美谷科技股份有限公司 监事会 二〇二五年八月二十六日 ...

证券代码：000615 证券简称：*ST美谷 公告编号：2025-073 奥园美谷科技股份有限公司 第十一届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 审议通过了《2025 年半年度报告全文及摘要》 经审议，董事会认为：公司《2025 年半年度报告全文》及摘要的编制程序 符合法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在虚假记载、误导性陈述或者重大遗 漏。具体内容详见同日刊登于《证券时报》和巨潮资讯网（www.cninfo.com.cn， 下同）的《2025 年半年度报告摘要》及巨潮资讯网的《2025 年半年度报告全文》。 表决结果：9 票同意，0 票反对，0 票弃权。 特此公告。 奥园美谷科技股份有限公司 董事会 二〇二五年八月二十六日 1 奥园美谷科技股份有限公司（以下简称"公司"）第十一届董事会第二十五 次会议通知于 2025 年 8 月 16 日上午以电子通讯方式通知公司全体董事，会议于 2025 年 8 月 26 日上午以现场结合电子通讯方式召开。本次会 ...

Market Overview - The medical beauty sector experienced a decline of 3.11% on August 27, with Aimeike leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Aimeike (300896) closed at 190.03, down 3.88%, with a trading volume of 62,200 shares and a transaction value of 1.207 billion yuan [1] - Huaxi Biological (688363) closed at 56.87, down 2.25%, with a trading volume of 99,400 shares and a transaction value of 580 million yuan [1] - Jinbo Biological (832982) closed at 304.80, down 3.24%, with a trading volume of 10,300 shares and a transaction value of 319 million yuan [1] - ST Meigu (000615) remained unchanged at 3.33, with a trading volume of 142,300 shares and a transaction value of 47.7013 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 199 million yuan from main funds, while retail investors contributed a net inflow of 153 million yuan [1] - Aimeike experienced a net outflow of 143 million yuan from main funds, with retail investors contributing a net inflow of 98.8281 million yuan [2] - Huaxi Biological had a net outflow of 57.973 million yuan from main funds, but a net inflow of 53.4443 million yuan from retail investors [2]

Market Overview - The Shanghai Composite Index is at 3884.87 points, above the six-month moving average, with a slight increase of 0.03% [1] - The total trading volume of A-shares today is 21,403.55 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 47 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Haosheng Electronics (12.03%) - Senqilin (4.06%) - Shuguang Co., Ltd. (3.72%) [1] Stock Performance Data - The following stocks have notable performance metrics: - Haosheng Electronics: Today's increase of 14.32%, turnover rate of 7.33%, six-month average price of 21.38 yuan, latest price at 23.95 yuan [1] - Senqilin: Today's increase of 5.90%, turnover rate of 6.52%, six-month average price of 20.00 yuan, latest price at 20.81 yuan [1] - Shuguang Co., Ltd.: Today's increase of 5.15%, turnover rate of 10.89%, six-month average price of 3.74 yuan, latest price at 3.88 yuan [1]

Market Overview - The Shanghai Composite Index closed at 3888.00 points, above the six-month moving average, with a slight increase of 0.11% [1] - The total trading volume of A-shares reached 16993.57 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 46 A-shares have surpassed the six-month moving average today, with notable stocks including Shuguang Co., Zhengdan Co., and Dongbai Group, showing divergence rates of 4.78%, 4.68%, and 2.88% respectively [1] - Stocks with smaller divergence rates that have just crossed the six-month moving average include Jinjiang Hotels, Mingchen Health, and Spring Airlines [1] Top Stocks by Divergence Rate - The top three stocks with the highest divergence rates are: - Shuguang Co. (600303) with a price increase of 6.23%, turnover rate of 9.78%, six-month line at 3.74 yuan, latest price at 3.92 yuan, and a divergence rate of 4.78% [1] - Zhengdan Co. (300641) with a price increase of 6.11%, turnover rate of 6.57%, six-month line at 24.40 yuan, latest price at 25.54 yuan, and a divergence rate of 4.68% [1] - Dongbai Group (600693) with a price increase of 3.53%, turnover rate of 5.38%, six-month line at 6.27 yuan, latest price at 6.45 yuan, and a divergence rate of 2.88% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Tianbang Food (002124) with a price increase of 3.30%, turnover rate of 4.80%, six-month line at 3.05 yuan, latest price at 3.13 yuan, and a divergence rate of 2.74% [1] - *ST Haiyuan (002529) with a price increase of 5.06%, turnover rate of 1.38%, six-month line at 6.68 yuan, latest price at 6.85 yuan, and a divergence rate of 2.53% [1] - Senqilin (002984) with a price increase of 4.22%, turnover rate of 4.06%, six-month line at 20.00 yuan, latest price at 20.48 yuan, and a divergence rate of 2.43% [1]

Group 1 - The medical beauty sector increased by 0.48% on August 25, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - The trading volume and turnover for key stocks in the medical beauty sector were reported, with Aimeike and Huaxi Biological showing notable figures [1] Group 2 - The net inflow of main funds in the medical beauty sector was 11.25 million yuan, while retail investors saw a net inflow of 37.19 million yuan [1] - Aimeike had a main fund net inflow of 5.73 million yuan, but a significant outflow from speculative funds of 36.09 million yuan [2] - Huaxi Biological experienced a main fund net inflow of 4.79 million yuan, with a minor outflow from speculative funds [2]

Group 1 - The core viewpoint of the article highlights the fluctuating investment and financing trends in China's medical beauty industry, with a peak in 2016 and a decline thereafter [1][17] - Investment events peaked in 2016 with 19 occurrences and an investment amount of 1.353 billion RMB, while the highest investment amount was recorded in 2018 at 2.374 billion RMB [1] - By 2024, only 3 investment events occurred with a total investment of 150 million RMB, and as of June 5, 2025, only 1 event with an investment of 30 million RMB was reported [1] Group 2 - The majority of investment rounds in the medical beauty industry are concentrated in early stages, particularly angel and A-round financing [2] - The industry encompasses various fields such as medical beauty raw materials, equipment, and service platforms, indicating strong innovation and technical barriers [2] Group 3 - Investment activities are primarily concentrated in Beijing and Guangdong, with 49 and 23 financing events respectively, followed by Sichuan and Shanghai with 12 and 9 events [4] - The focus on these regions is attributed to the concentration of resources and opportunities in the medical beauty sector [4] Group 4 - The investment direction is primarily focused on the construction of medical beauty platforms [6] Group 5 - The main investment entities in the medical beauty industry are capital organizations, accounting for 73% of the total, while industrial entities like Gree Electric and Xiaomi Group make up 27% [5] Group 6 - There are few industry investment funds specifically targeting medical beauty, with only 2 private funds identified [13] Group 7 - Recent years have seen a trend of horizontal acquisitions among midstream enterprises in the medical beauty industry as a means to expand scale [15] - Notable acquisition events include 康哲药业 acquiring 旭俐医疗 with a 100% stake and 新氧 acquiring 奇致激光 [16] Group 8 - Overall, the investment and financing landscape in China's medical beauty industry has shown fluctuations, with a concentration of activities in Beijing and Guangdong, primarily driven by capital investment institutions [17]

奥园美谷科技股份有限公司 证券代码：000615 证券简称：*ST美谷 公告编号：2025-072 公司对此次调整定期报告披露时间给投资者带来的不便致以诚挚的歉意，敬 请广大投资者谅解。 奥园美谷科技股份有限公司 关于延期披露 2025 年半年度报告的公告 董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 二〇二五年八月二十二日 奥园美谷科技股份有限公司（以下简称"公司"）原定于 2025 年 8 月 26 日披露《2025 年半年度报告》，为进一步完善半年度报告编制和复核的相关工 作，确保半年度报告披露的真实性、准确性和完整性，基于谨慎考虑，经向深圳 证券交易所申请，公司将《2025 年半年度报告》的披露时间延期至 2025 年 8 月 28 日。 1 公司指定的信息披露媒体为《证券时报》和巨潮资讯网（www.cninfo.com.cn）， 有关信息均以公司在前述指定媒体刊登的公告为准，敬请广大投资者谨慎决策， 注意投资风险。 特此公告。 ...